BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27974417)

  • 1. Notch Inhibitor Shows Modest Efficacy.
    Cancer Discov; 2017 Feb; 7(2):OF3. PubMed ID: 27974417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer.
    Massard C; Azaro A; Soria JC; Lassen U; Le Tourneau C; Sarker D; Smith C; Ohnmacht U; Oakley G; Patel BKR; Yuen ESM; Benhadji KA; Rodon J
    Ann Oncol; 2018 Sep; 29(9):1911-1917. PubMed ID: 30060061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling.
    Ferrarotto R; Mishra V; Herz E; Yaacov A; Solomon O; Rauch R; Mondshine A; Motin M; Leibovich-Rivkin T; Davis M; Kaye J; Weber CR; Shen L; Pearson AT; Rosenberg AJ; Chen X; Singh A; Aster JC; Agrawal N; Izumchenko E
    Cell Death Dis; 2022 Aug; 13(8):678. PubMed ID: 35931701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.
    Stoeck A; Lejnine S; Truong A; Pan L; Wang H; Zang C; Yuan J; Ware C; MacLean J; Garrett-Engele PW; Kluk M; Laskey J; Haines BB; Moskaluk C; Zawel L; Fawell S; Gilliland G; Zhang T; Kremer BE; Knoechel B; Bernstein BE; Pear WS; Liu XS; Aster JC; Sathyanarayanan S
    Cancer Discov; 2014 Oct; 4(10):1154-67. PubMed ID: 25104330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies.
    Nefedova Y; Gabrilovich D
    Drug Resist Updat; 2008 Dec; 11(6):210-8. PubMed ID: 18951834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecules that inhibit Notch signaling.
    De Kloe GE; De Strooper B
    Methods Mol Biol; 2014; 1187():311-22. PubMed ID: 25053499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer.
    Pant S; Jones SF; Kurkjian CD; Infante JR; Moore KN; Burris HA; McMeekin DS; Benhadji KA; Patel BKR; Frenzel MJ; Kursar JD; Zamek-Gliszczynski MJ; Yuen ESM; Chan EM; Bendell JC
    Eur J Cancer; 2016 Mar; 56():1-9. PubMed ID: 26798966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.
    Even C; Lassen U; Merchan J; Le Tourneau C; Soria JC; Ferte C; Ricci F; Diener JT; Yuen E; Smith C; Oakley GJ; Benhadji KA; Massard C
    Invest New Drugs; 2020 Apr; 38(2):402-409. PubMed ID: 30953269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting Notch Activity in Breast Cancer Stem Cells by Glucose Functionalized Nanoparticles Carrying γ-secretase Inhibitors.
    Mamaeva V; Niemi R; Beck M; Özliseli E; Desai D; Landor S; Gronroos T; Kronqvist P; Pettersen IK; McCormack E; Rosenholm JM; Linden M; Sahlgren C
    Mol Ther; 2016 May; 24(5):926-36. PubMed ID: 26916284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
    Efferson CL; Winkelmann CT; Ware C; Sullivan T; Giampaoli S; Tammam J; Patel S; Mesiti G; Reilly JF; Gibson RE; Buser C; Yeatman T; Coppola D; Winter C; Clark EA; Draetta GF; Strack PR; Majumder PK
    Cancer Res; 2010 Mar; 70(6):2476-84. PubMed ID: 20197467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notch inhibition restores TRAIL-mediated apoptosis via AP1-dependent upregulation of DR4 and DR5 TRAIL receptors in MDA-MB-231 breast cancer cells.
    Portanova P; Notaro A; Pellerito O; Sabella S; Giuliano M; Calvaruso G
    Int J Oncol; 2013 Jul; 43(1):121-30. PubMed ID: 23686163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation.
    Grudzien P; Lo S; Albain KS; Robinson P; Rajan P; Strack PR; Golde TE; Miele L; Foreman KE
    Anticancer Res; 2010 Oct; 30(10):3853-67. PubMed ID: 21036696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
    Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
    Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.
    Konishi J; Kawaguchi KS; Vo H; Haruki N; Gonzalez A; Carbone DP; Dang TP
    Cancer Res; 2007 Sep; 67(17):8051-7. PubMed ID: 17804716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study on Notch signaling in human breast cancer.
    Zang S; Ji Ch; Qu X; Dong X; Ma D; Ye J; Ma R; Dai J; Guo D
    Neoplasma; 2007; 54(4):304-10. PubMed ID: 17822320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy.
    Liu J; Mao Z; Huang J; Xie S; Liu T; Mao Z
    Biochem Biophys Res Commun; 2014 Feb; 444(4):670-5. PubMed ID: 24502949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials.
    Shi W; Harris AL
    J Mammary Gland Biol Neoplasia; 2006 Jan; 11(1):41-52. PubMed ID: 16947085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Notch Signaling: A Potential Therapeutic Target for Hematologic Malignancies.
    Gao L; Yuan K; Ding W; Lin M
    Crit Rev Eukaryot Gene Expr; 2016; 26(3):239-46. PubMed ID: 27650987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of the notch signaling pathway by γ-secretase inhibitor GSI inhibits human nasopharyngeal carcinoma cell proliferation.
    Chen SM; Liu JP; Zhou JX; Chen C; Deng YQ; Wang Y; Tao ZZ
    Cancer Lett; 2011 Jul; 306(1):76-84. PubMed ID: 21420785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of gamma-secretase affects proliferation of leukemia and hepatoma cell lines through Notch signaling.
    Suwanjunee S; Wongchana W; Palaga T
    Anticancer Drugs; 2008 Jun; 19(5):477-86. PubMed ID: 18418214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.